冠状腺增生症中的心血管风险:系统性审查
Irene Lo1,2, Shraddha Meti1,2, Avril Mason1
1Department of Paediatric Endocrinology, Royal Hospital for Children, Glasgow, UK.
Journal of medical genetics
|October 30, 2025
概括
无骨质形成症患者面临更高的肥胖,高血压和葡萄糖调节受损的风险,导致心血管疾病 (CVD) 问题. 需要进一步的研究,以充分理解心血管疾病的发展和死亡率在这个人群中.
科学领域:
- 医学研究 医学研究
- 遗传学 是一个遗传学.
- 心脏病学 心脏病学
背景情况:
- 无粒细胞增生是不成比例的矮身最常见的原因,与预期寿命的缩短有关.
- 心血管疾病 (CVD) 对这种寿命缩短的具体贡献还不清楚.
研究的目的:
- 系统地审查和识别被诊断患有无粒细胞增生症的个体中心血管疾病 (CVD) 的患病率.
主要方法:
- 按照PRISMA指南进行了一次系统的文献审查,由两位独立审稿人进行.
- 在两个数据库中进行了搜索,没有语言或日期限制,使用与形质疏松症和心血管健康相关的术语.
- 包含的研究的质量评估是使用关键评估技能计划的检查清单进行的.
主要成果:
- 分析了33项研究 (发表于1972-2023年),涉及超过5000名患有无形质症的个人.
- 通常评估的心血管风险因素包括脂肪 (61%),代谢参数 (27%) 和血压 (18%).
- 患有无骨质形成症的个体表现出肥胖,葡萄糖调节受损和高血压的风险增加.
结论:
- 在心血管疾病 (CVD) 风险如何在无形质形成症中测量存在显著的异质性,造成了文献上的差距.
- 进一步的纵向研究与详细的心血管表型是必不可少的,以了解心血管疾病的发展,并减轻与之相关的风险在骨质疏松症.
- 应对心血管疾病风险对于改善无形质形成症患者的发病率和死亡率结果至关重要.
相关概念视频
01:30Coronary Artery Disease I: Introduction
868
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
868
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
387
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
387
01:29Cardiovascular System Abnormal Findings I: Inspection and Palpation
801
In a cardiovascular examination, inspection and palpation are crucial for identifying abnormalities.
Abnormal findings observed during an inspection
Abnormal findings observed during an inspection
801
01:26Atherosclerosis III: Management
311
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
311
01:27Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
452
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
452
01:25Aortic Regurgitation III: Medical Management
385
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
385